DAY 2
Thursday June 20, 2024
7:00 am
Workshop B: Advancing Translational Models for Improving Predictive Validity Within Innate Immune System-Targeted Therapies
Synopsis
This workshop aims to bridge the translational gap in the development of therapies targeting the innate immune system, with a specific focus on STING & TLR receptors. Attendees will gain insights into selecting, utilizing and validating translational models for effective translation of preclinical findings into clinical success.
Overview of suitable preclinical models for evaluating STING & TLR-targeted therapies
- Reviewing the advantages and limitations of in vitro, in vivo, and ex vivo models in translational research
- Highlighting novelty in humanized and organoid models for mimicking innate immune system responses
- Bridging preclinical insights to clinical translation
Translating preclinical findings into actionable insights for clinical trial design
- Addressing challenges and strategies in extrapolating preclinical efficacy to human applications
- Integrating multiple translational models for comprehensive therapy assessment
- Incorporating advanced technologies in translational research
Utilizing imaging, omics, and molecular profiling in translational model development
- Modeling immune-tumor interactions and microenvironment complexities in vitro and in vivo
- Showcasing advancements in bioengineering approaches for enhanced translational relevance
- Validating translational models for innate immune system therapies
More speakers to be announced!
9:00 am Chairs Opening Remarks
Exploring Innovations in Systemic Approaches for Striking the Balance Between Safety & Efficacy
9:15 am Hitting Multiple Immune System Targets with a Passively Targeted, Pulsed, Systemic Approach to Amplify Efficacy & Widen the Therapeutic Index
Synopsis
- Taking advantage of multiple TLR/STING agonists, passive targeting and rapid clearance associated with bacteria
- Activation of both innate and adaptive anti-tumor immunity, tumor eradication and immunological memory in pre-clinical models
- Confirmation of a pulse-prime mechanism and update on a Phase 1 clinical trial with Decoy20
9:45 am Initial Promising Data With a Systemically Administered TLR 7 & 8 Coagonist (EIK1001)
Synopsis
- Understand the scientific rationale behind EIK1001, a systemically administered agonist of toll-like receptors 7 and 8
- Analyze single-agent activity data as well as activity in combination with anti-PD-1 agents across multiple solid tumor types
- Discuss the program advancing into late stage development
10:15 am Morning Break
11:00 am Introduction of GQ Technologies for iDevelopment of Next Generation AIAC/ISAC
Synopsis
- GQ1007 preclinical development and characterization
- GQ1007 preclinical safety assessment
- dpADC as the next generation dual payload AIAC platform
11:30 am Building TLR7 Targeted Immune Agonists
Synopsis
- Examine the scientific rationale behind targeted immune agonists (TIA) targeting TLR7
- Assess the design of TIA conjugates and characterization of in vitro and in vivo functional activity
- Develop preclinical tools to de-risk TIAs potential for induction of immune-related adverse effects
12:00 pm Lunch
Exploring Progression & Transferable Insights in Uses for STING & TLR Targeted Therapies Beyond Oncology
1:00 pm Evaluation of an Oral TLR7 Agonist as Part of a Combination HIV Cure Strategy
Synopsis
- Vesatolimod (VES), an oral, selective TLR7 agonist
- TLR7 activation contributes to remission and/or cure in preclinical models for HIV
- Clinical development of VES for HIV cure
1:30 pm PRTX007, A Novel Orally Administered TLR7 Agonist Prodrug from Primmune Therapeutics for the Treatment of Serious Human Diseases
2:00 pm Afternoon Break
Harnessing Preclinical & Translational Insights to bridge the Translational Gap & Generate In-Human Success of Innate Immune Targeted Therapies
3:00 pm Progress of Dual Action Tumor Immune Agonists to Produce a Durable Clinical Response for Treatment of Solid Tumors
Synopsis
- Harnessing the viability of tumor cells to produce cytokines that activate the innate immune system
- Modulating the potency and half-life of immune agonists for optimized antitumor efficacy and systematic tolerability
- Providing tumor neoatigens in situ to guide development of the emerging adaptive immune system
- Tipping the balance and break down barriers in the microenvironment of solid tumors to improve the activity and infiltration of immune cells
3:30 pm Developing a Systemically Delivered TLR2 Agonist for Cancer Immunotherapy
Synopsis
- Understand the mechanistic rationale for pursuing TLR2 agonists in CPI resistant solid tumor indications
- Review the safety and tolerability profile of AXA-042 demonstrated in the first-in-human clinical trial
- Translational lessons from the clinic: impact of TLR2 target engagement on clinical safety and response biomarkers